Nektar Therapeutics NKTR EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Nektar Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nektar Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nektar Therapeutics's EBITDA margin?
- Nektar Therapeutics (NKTR) reported EBITDA margin of -240.6% in Q1 2026.
- How has Nektar Therapeutics's EBITDA margin changed year-over-year?
- Nektar Therapeutics's EBITDA margin decreased by 67.4% year-over-year, from -143.8% to -240.6%.
- What is the long-term trend for Nektar Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Nektar Therapeutics's EBITDA margin has grown at a -1.3% compound annual growth rate (CAGR), from -268.7% to -251.8%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.